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Recent studies have established that members of the 
caspase protease family are essential components of a 
conserved cell death program. Insights into their 
biological roles, structure and mechanism are enabling 
investigators to begin to explore the therapeutic 
potential of caspase inhibition. 
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Introduction 
Apoptosis is the highly conserved mechanism by which 
eukaryotic cells commit suicide (for review see [l]). Over 
the past few years, it has emerged as one of the hottest 
areas of research in cell biology as the importance of the 
process in the proper development and physiological well- 
being of mammals has become recognized. For example, 
apoptosis is required for normal tissue turnover, for the 
proper development and maintenance of the immune sys- 
tem, and for the elimination of virus-infected cells. It 
follows that inopportune or insufficient apoptosis is be- 
lieved to result in several pathologies for which there are 
currently no good therapies [Z], such as cancer and autoim- 
mune disorders, which may result from a failure of cells to 
undergo apoptosis, ischemic injury and at least some neu- 
rodegenerative disorders, which instead may result from 
excessive apoptosis. The potential medical impact that 
would result from the effective treatment of any one of 
these pathologies is the driving force for investigators in 
this intensely competitive field. 
Apoptosis is an extremely well-ordered process that is char- 
acterized by DNA fragmentation, chromatin condensation, 
membrane blebbing and cell shrinkage. Cells undergoing 
apoptosis ultimately disassemble into membrane-enclosed 
vesicles (apoptotic bodies) that are engulfed by neighbor- 
ing cells and phagocytes, thus preventing an inflammatory 
response. In the past few years enormous progress has 
been made in elucidating the biochemical events that con- 
tribute to this complex, tightly regulated phenomenon, 
largely stemming from the pivotal observation in 1993 that 
CED-3, the product of a gene that is absolutely required 
for cell death in the nematode Caenorhabditis elegans, is 
related to the mammalian cysteine protease interleukin-lB 
converting enzyme (ICE, caspase-1) [3]. This finding not 
only confirmed earlier work suggesting that the mechanism 
of cell death is largely conserved across species, but also 
provided the first evidence that proteases are integral to 
the death program. 
Caspase-1 was first identified in 1989 [4,5] as the enzyme 
responsible for the processing of the pro-inflammatory 
cytokine pro-interleukin-1B in monocytes. When this 
protein was first purified and sequenced in 1992 [6,7], it 
was found to be unrelated to any known protease. The 
report of the relationship between caspase-1 and CED-3 
[3] prompted a frenetic search for other mammalian cas- 
pases; to date, ten homologs of human origin have been 
described. Members of the caspase family clearly have 
prominent and distinct biological functions in inflamma- 
tion and apoptosis. For example, caspase-l-deficient 
mice are defective in the production of several inflamma- 
tory cytokines, but they have no major defect in apopto- 
sis [8,9]. In contrast, mice that are deficient in caspase3, 
the mammalian homolog most closely related to CED-3, 
have a profound defect in the apoptosis that occurs 
during neuronal development [lo]. 
Concerning the biochemical mechanisms that result in the 
apoptotic phenotype, it appears that diverse signaling 
pathways are engaged in apoptosis (depending on the 
stimulus employed and cell type), and they converge upon 
a common effector pathway that results in hydrolysis of a 
number of key structural and housekeeping proteins (for 
review see [ 111). In general, cleavage of the target protein 
occurs at a single site and results in either gain or loss of 
activity. Caspases appear to be involved in both the effec- 
tor phase of apoptosis, where they are responsible for 
most, if not all, of these cleavage events, and in at least 
some of the upstream signaling pathways, where they 
become activated and, in turn, activate the caspases 
involved in the effector phase. 
Because of the central role of caspases in important physio- 
logical processes, and the possibility that caspase inhibitors 
may be effective therapeutic agents, these enzymes have 
been the subject of intense scrutiny. This review summa- 
rizes current understanding of the structure, catalytic 
mechanism, specificity and inhibition of these important 
biological mediators. 
Catalytic mechanism and structure 
The two most distinct members of the caspase family, 
caspase-1 and caspase-3, have been purified from natural 
sources and cloned, and their structures have been 
determined using X-ray crystallography [6,12-151. The 
results of these studies, together with a comparison of the 
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Figure 1 
The structures of members of the caspase family. Structures of 
(a) caspase-3 and (b) caspase-1 in complex with tetrapeptide 
aldehyde inhibitors (yellow). The tetramers are composed of two 
heterodimeric catalytic domains (blue/red and green/pink). The large 
(blue/green) and small (red/pink) subunits of the heterodimer both 
contribute key residues to the active site. The most obvious difference 
between the two structures is the presence of a surface loop in 
caspase-3 (indicated with an arrow), not present in caspase-1, that 
forms one side of the S, subsite. A comparison of S, in (c) caspase-3 
and (d) caspase-1 reveals the structural basis for the distinct 
specificities of these two enzymes, Schematic representations of the 
active sites of (e) caspase-3 and (f) caspase-I in complex with 
aldehyde inhibitors illustrate the extent to which both subunits 
contribute residues important for binding and catalysis. (a-d) 
Reproduced with permission from [l 11. 
primary sequences of all of known caspases, suggest that 
caspases have a number of distinguishing catalytic and 
structural properties. 
The catalytic domain is a heterodimer composed of a large 
subunit of 17-21 kDa and a smaller subunit of lo-13 kDa. 
In the crystal structures of caspase-1 and caspase-3 in 
complex with inhibitors, two heterodimers associate to 
form a tetramer and at least some evidence suggests that 
this is the active form of the enzyme in solution (Figure 1) 
[13]. Within each heterodimer, the two subunits are inti- 
mately associated to form a single catalytic domain com- 
posed of a central six-stranded B sheet core flanked on 
either side by a helices. The active site, which lies in a 
groove on the surface of the protein, is comprised of 
residues from both large and small subunits. 
An analysis of the active site in complex with tetrapep- 
tide-based inhibitors defines those residues that are 
important for binding and catalysis, and suggests that cas- 
pases use a typical cysteine-protease mechanism. Specifi- 
cally, catalysis involves a catalytic diad composed of a 
cysteine nucleophile (CysZ85) in close proximity to a histi- 
dine imidazole group (His237), which is believed to facili- 
tate catalysis via a general acid/base function. The 
putative oxyanion hole, which may be involved in the sta- 
bilization of the oxyanion of the tetrahedral intermediates 
formed during catalysis, is formed by the backbone amide 
protons of the active site cysteine residue and GlyZ38. 
Like many other proteases, caspases are synthesized as pro- 
enzymes that are proteolytically activated to form the 
mature protein. In addition to the large and small subunits 
of the heterodimer, the pro-enzyme also has an amino-ter- 
minal domain of variable length (Z-25 kDa), and, in some 
cases, a short linker peptide between the large and small 
subunits. All of these domains are partitioned by Asp-X 
bonds. As described in detail below, caspases are distin- 
guished among proteases by their stringent specificity for 
cleavage after aspartic acid residues, suggesting that activa- 
tion is autocatalytic, mediated by an enzyme with a similar 
specificity (e.g., another caspase), or both. Evidence that 
both activation mechanisms occur in &o has been obtained 
from models of Fas-induced apoptosis. 
Specificity 
Caspases are among the most specific of proteases. They 
have a near absolute requirement for aspartic acid in the S, 
subsite, such that substitution of any other amino acid 
(including glutamic acid) leads to > loo-fold reduction in 
catalytic efficiency [16,17]. This stringent specificity can be 
attributed to hydrogen-bonding interactions between aspar- 
tic acid and three residues of the caspase, Arg179, Gln283 
and Arg341, contributed by both subunits (Figure le,f). 
Other than caspases, the only mammalian protease known 
to have a similar specificity is the cytotoxic lymphocyte- 
derived serine protease granzyme B, another important 
mediator of apoptosis (where it has been implicated in the 
activation of caspases). 
Caspases have an equally stringent specificity for at least 
four amino acids to the left of the cleavage site [6], and it is 
clear that primary sequence recognition is a necessary 
requirement for catalysis. It follows, given the diverse bio- 
logical behavior of caspases, that the extended amino-acid 
preferences of members of this family are quite distinct. 
Recently, an intimate understanding of the tetrapeptide 
specificities of all ten human caspases was obtained using a 
positional-scanning combinatorial substrate library (PS- 
CSL; Figure 2) [l&19]. The results divide these enzymes 
into three major groups, and indicate that the S, subsite is 
the single most important determinant of specificity 
among caspases. Group I caspases (1, 4 and 5), all favor 
hydrophobic amino acids in S,, with an optimal sequence 
of Trp-Glu-His-Asp (WEHD). Group II enzymes (2, 3, 7 
and C. &guns CED-3) have a strict requirement for aspar- 
tic acid in S,, preferring the sequence Asp-Glu-X-Asp 
(DEXD). Caspases in group III tolerate many amino acids 
in S,, but have a marked preference for those with 
branched, aliphatic sidechains, and an optimal sequence of 
(Val,Leu)-Glu-X-Asp ((V,L)EXD). Within each group, 
the specific amino-acid preferences are exceedingly 
similar, in some cases identical, implying that at least some 
of these enzymes either have redundant functions, or are 
cell-type or tissue-specific isoforms. 
The structural basis for the distinct specificities of the two 
most diverse caspases (1 and 3) is evident from a compari- 
son of their crystal structures [13-151. In general, the ter- 
tiary and quaternary structures of the enzymes are quite 
comparable, as are the positions of the catalytic residues 
and components of the S, subsites. In contrast, there are 
striking differences in the geometry and chemical composi- 
tion of S, that account for the different specificities of 
these enzymes and, ultimately, their distinct biological 
functions (Figure lc,d). In caspase-1, S, is a shallow groove 
on the surface of the protein that easily accommodates 
Rl 00 Chemistry & Biology 1998, Vol 5 No 5 
Figure 2 
Optimal sequence 
P4 P3 P2 PI 
Group I: 
mediators of inflammation 
Caspase-I W E H D 
Caspase-4 WorL E H D 
Caspased WorL E H D 
Group II: 
effecters of apoptosis 
C. elegansCED-3 D E T D 
Caspase-3 D E V D 
Caspase-7 D E v D 
Caspase-2 D E H D 
Group Ill: 
activators of apoptosis 
Caspase-6 V E H D 
Caspase-8 L E T D 
Caspase-9 L E H D 
Caspase-I 0 L E Nle D 
Putative macromolecular substrates and cleavage sequences 
P4 P3 P2 PI Substrate 
F E A D Pro-interleukin-I f3 site I 
Y V H D Pro-interleukin-16 site II 
Pro-inflammatory cytokines 
L E S D Interferon? inducing factor 
W X X D Group I proenzymes 
-I 
D E VD Poly(ADP-ribose) polymerase 
D E P D Sterol regulatory element-binding protein 
D EVD DNA-dependent protein kinase,, Homeostatic, 
repair and 
D G P D 70 kDa Ul small ribonucleoprotein 
structural proteins 
D E L D D4 G-protein dissociation inhibitor 
D E A D Retinoblastoma protein 
J 
- 
I E TD Caspase-3 proenzyme 
I Q AD Caspase-7 proenzyme 
Group II proenzymes, 
nuclear lamins 
V E I D Lamin A 
Chemistty & Biology 
Tetrapeptide specificities define three functional groups. The amino-acid 
preferences of caspases within each group are exceedingly similar, in 
some cases identical, implying that at least some of these enzymes have 
redundant functions. A comparison of tetrapeptide specificities with 
cleavage sequences in a subset of the known endogenous caspase 
substrates suggests that group I caspases are mediators of 
inflammation, where they are responsible for cleavage of several pro- 
inflammatory cytokines. In contrast, group II and group Ill caspases 
appear to function primarily in apoptosis, where they are involved in 
effector processes and upstream signalling events, respectively. 
hydrophobic amino acids, explaining the relatively promis- 
cuous nature of this subsite. In caspase-3, S, is significantly 
smaller and contains a network of hydrogen bonds that 
serve to stabilize the P4-Asp of its substrates. With regard 
to S,, the preference of all caspases for glutamic acid in this 
position is explained by the observation that one of the 
arginine residues (Arg341) involved in stabilization of the 
P, aspartic acid of ligands is appropriately positioned to 
form a salt link with glutamic acid in P, (Figure le). 
It is clear from several lines of evidence that the substrate 
specificity observed for tetrapeptides also extends to 
macromolecules. Most compelling, in cases where endoge- 
nous substrates for particular caspases are known, the 
tetrapeptide sequence at the cleavage sites are similar or 
identical to the optimal sequence determined by PS-CSL. 
Additionally, for caspase-1 and caspase-3, the k,.JK, for 
cleavage of tetrapeptide substrates (> 106M-1 s-r) is great- 
er than or equal to the corresponding rate of cleavage of 
their macromolecular substrates. Consequently, the 
tetrapeptide specificities provide important clues about the 
biological functions and relationships between these 
enzymes. Based on these results, and those from numerous 
biochemical and genetic studies, functional relationships 
between these enzymes can be tentatively assigned. 
Group I caspases function primarily as mediators of inflam- 
mation, where they are involved in the proteolytic activa- 
tion of pro-inflammatory cytokines. Group II caspases, and 
probably caspase-6, are mediators in the effector phase of 
apoptosis, where they are responsible for cleavage of key 
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Figure 3 
Peptide-based inhibitors. Several classes of 
reversible and irreversible peptide-based 
inhibitors have been identified for caspases 
using strategies that have proven successful 
for inhibition of other cysteine proteases. The 
most potent contain a tetrapeptide that is 
optimal for the enzyme of interest. Aldehyde, 
nitriles and ketones form covalent adducts 
with the catalytic cysteine (thiohemiacetal, 
thioimidate and thiohemiketal, respectively) 
that are readily hydrolyzed and function as 
fully reversible inhibitors. The irreversible 
inhibitors that have been described are 
a-substituted ketones; inactivation is believed 
to proceed through formation of a 
thiohemiketal, with subsequent displacement 
of the cx substituent by the active-site cysteine 
to form a thiomethylketone. 
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structural and homeostatic proteins. Group III caspases, 
with the possible exception of caspase-6, are involved in 
signaling pathways where they function as upstream acti- 
vators of the effector caspases. 
Inhibitors 
Elegant work in the area of cysteine protease inhibition 
has resulted in the identification of several classes of 
electrophiles that form both reversible and irreversible 
adducts with the active-site cysteine residue (for reviews 
see [ZO,Zl]). Reversible inhibitors include aldehydes, 
ketones, and nitriles, whereas irreversible inhibitors are 
generally a-substituted ketones, and include diazomethyl- 
ketones, halomethylketones and acyloxymethylketones. 
All of these inhibitor strategies have proven successful in 
efforts to identify caspase inhibitors (Figure 3). 
The most potent inhibitors contain a peptide that is 
optimal for its target caspase. For example, the tetrapep- 
tide aldehyde AC-WEHD-CHO, containing the optimal 
recognition sequence for caspase-1, has a dissociation 
constant (Ki) for this enzyme of 56 pM [18]. Similarly, the 
K for inhibition of caspase-3 by AC-DEVD-CHO is 
230 pM [12]. Surprisingly, aldehydes do not appear to 
bind in a transition-state conformation, in which the 
oxyanion of the thiohemiacetal is stabilized in the puta- 
tive oxyanion hole; instead, the oxyanion participates in a 
hydrogen-bond network involving the catalytic histidine 
residue (Figure le,f). 
Although aldehydes are the most potent reversible 
peptide-based inhibitors that have been described for these 
enzymes, others, most notably ketones, are remarkably 
efficient; a tetrapeptide phenylpentyl ketone inhibitor of 
caspase-1 has a dissociation constant of 18.5 nM [Z]. The 
use of ketones also allows specificity- and affinity-enhanc- 
ing substituents to be accommodated on both sides of the 
carbonyl group. 
Among irreversible caspase inhibitors, acyloxymethyl- 
ketones and their derivatives are by far the most well 
explored, and the most interesting. These compounds, 
which were first described as potent Cathepsin B 
inhibitors [23,24], are highly efficient caspase inactiva- 
tars, having typical second-order rate constants for inacti- 
vation of 1 x lo6 M-l s-l (for examples see [25]). Despite 
their reactivity with caspases, acyloxymethylketones and 
their derivatives are relatively inert towards other biolog- 
ical nucleophiles, making them excellent probes for bio- 
logical functions of caspases z’n U&O and in whole-cell 
models of apoptosis. 
Efforts to make nonpeptide counterparts of these inhibitor 
classes have exploited the results of structural studies that 
suggested that hydrogen bonds involving PI-NH, P,--NH, 
and P,-CO of tetrapeptide inhibitors are important for 
binding, whereas the P,NH is dispensable. These obser- 
vations have led to the identification of nonpeptidyl 
inhibitors in which the P, amino acid is replaced with a 
pyridone derivative with no significant adverse effect on 
potency [26]. More recently, this work as been extended to 
the identification of pyridazinodiazepines as potent, P,-P, 
peptidomimetic caspase inhibitors [27]. 
’ In fact, inhibition of caspases is not only a lucrative 
prospect for chemists and biologists interested in treatment 
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of disease, but it is also favorable for viruses. Both apopto- 
sis and inflammation are triggered in response to viral 
infection, and inhibition of these processes facilitates repli- 
cation of the pathogen. It is therefore not surprising that 
several viral caspase inhibitors have been identified. 
Cytokine response modifier A (CrmA) is a 38 kDa serpin 
from cowpox virus that has been shown to be a potent 
inhibitor of group I, and some group III, caspases, having 
Ki values ranging from IO pM to 20 nM [28,29] (N.A.T. 
and M. Garcia-Calvo, unpublished observations). This 
selectivity suggests that cowpox virus facilitates infection 
through both inhibition of the host inflammatory response 
and inhibition of apoptosis. A baculovirus gene product, 
~35, also appears to attenuate apoptosis via caspase inhibi- 
tion [30]. Finally, members of the IAP (inhibitor of apopto- 
sis) gene family encode potent inhibitors of the effecters 
caspase-3 and caspase-7 [31]. In the case of the IAPs, both 
viral and mammalian homologs have been described. Evi- 
dence for the importance of the human homolog, NAIP, 
has been obtained in studies of spinal muscular atrophy, 
which is associated with a mutation in the gene encoding 
this protein [32]. Taken together, the existence of multiple 
endogenous inhibitors of caspases, both viral and human, 
are a testament to the importance of these enzymes in 
maintaining our physiological well-being. 
Perspectives 
Knowledge of the structure, catalytic mechanism, and 
specificities of the caspases has led to the design of potent 
and selective inhibitors. A number of these compounds 
have been shown to be efficacious in animal models of dis- 
eases involving apoptosis and/or inflammation, which is 
encouraging news for investigators exploring the therapeu- 
tic potential of caspase inhibitors. In this regard, it is note- 
worthy that, in contrast to their potency in vitro, none of 
the reported inhibitors have good efficacy (IC,, < 1 PM) in 
whole-cell models of apoptosis and inflammation, so 
improving the physical properties of such compounds is a 
major challenge in this area. 
Attenuation of inflammation via selective caspase-1 inhibi- 
tion continues to be a key objective of several laboratories. 
Similarly, the increasing evidence that excessive apoptosis 
may be a major contributor to a number of serious disor- 
ders, and the identification of the caspases involved in this 
process, has resulted in several new research initiatives. At 
least initially, the use of caspase inhibitors may be limited 
to the treatment of acute disorders, given the importance 
of apoptosis in the maintenance of normal immune func- 
tion, the destruction of potentially tumorogenic cells and 
many other essential physiological processes. Hopefully, 
the prospects for treatment of chronic diseases will 
improve as more is learned about the biology of these 
enzymes, and with improvements in our abilities to target 
specific tissues and design selective inhibitors that have 
appropriate physical properties for long term use in viva. 
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